Inhibitors of VEGF (e.g., bevacizumab) or VEGFR and its signaling pathway have been developed with the aim to target the pathological tumor endothelium and thereby cut off the blood supply to tumors and deprive cancer cells of nutrients and oxygen [142]. This evidence concerns the gene KDR and cancer.